Marketing authorisation for Epistatus

Product Updates

Marketing authorisation for Epistatus

Special Products Ltd has announced that Epistatus 10 mg Oromucosal Solution (Midazolam) has been granted a UK marketing authorisation for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years who have been diagnosed with epilepsy.

Epistatus is presented “ready-to-use” in a novel, pre-filled, single-dose syringe, to provide carers with the confidence that they are administering the correct dose, the company says.

The pre-filled syringe, contained in tamper-evident packing, will be available to prescribe from August, 2017.

SPECIAL PRODUCTS 01932 690325

Record my learning outcomes

Product Updates

Share: